Targeted therapy in advanced colorectal cancer, an update

Targeted Oncology (Impact Factor: 3.46). 07/2007; 2(3):165-172. DOI: 10.1007/s11523-007-0052-7

ABSTRACT The introduction of inhibitors of signal transduction pathways has increased the therapeutic arsenal for patients with advanced
colorectal cancer (ACC). Bevacizumab, a monoclonal vascular endothelial growth factor antibody, is currently part of the standard
first-line treatment in combination with fluoropyrimidine-based chemotherapy. Cetuximab, a chimeric monoclonal antibody against
the epidermal growth factor receptor, has shown efficacy in irinotecan-refractory ACC patients. Several experimental targeted
agents, including small molecules that inhibit receptor tyrosine kinase activity, are currently being tested. We review the
mechanism of action as well as the current status of targeted therapy in ACC.